Sinovac Schedules 2010 Annual Meeting of Shareholders
Beijing — June 18, 2010 — Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines
in China, announced today that it will hold its 2010 Annual Meeting of Shareholders on Thursday, July 15, 2010
at 9:00 a.m. Beijing Time. The meeting will be held concurrently at No. 39 Shangdi Xi Road, Haidian District,
Beijing, PRC and at No. 6 Temple Street, St. John’s, Antigua. All shareholders of record as of May 26, 2010
will be eligible to vote and are invited to attend. Sinovac 2009 annual report and the proxy statements are also be
available on the company’s website:
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development,
manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac’s vaccine
products include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), and Anflu® (influenza). Panflu
TM , Sinovac’s pandemic influenza vaccine (H5N1), has already been approved for government stockpiling.
Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis vaccine,
and human rabies vaccine. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for
independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian,
focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies,
chickenpox, mumps and rubella vaccines for human use.
For more information, please contact:
Sinovac Biotech Ltd.
Amy Glynn/Stephanie Carrington
The Ruth Group